EG BioMed and YD Bio Launch AI-Based 10-Cancer RiskFactor Assessment

AI CANCER RISK
EG BioMed and YD Bio AI cancer risk assessment tool covering 10 cancer types

TAIPEI, Taiwan, Oct. 6, 2026 — Understanding your cancer risk shouldn’t require a blood draw, a scan, or a trip to a clinic.

EG BioMed and YD Bio Ltd. (NASDAQ: YDES) have launched the AI Cancer Risk Assessment, an online 52-question health survey that takes approximately 10 minutes to complete.

Drawing on information about an individual’s personal and family medical history, symptoms, lifestyle, environmental exposures, and diet, the assessment generates a personalized risk report covering 10 cancer types, providing users with greater insight into their individual cancer risk.

Accessible Cancer Risk Awareness, Anytime

The AI Cancer Risk Assessment consists of 52 structured questions covering personal health history, lifestyle habits, and family background. Upon completion, users receive a personalized risk report that highlights their relative risk level across each of the ten cancer types covered by the tool.

The tool is available at mdi.eg-bio.com at a promotional price of $10 USD. It is designed as an educational awareness resource to encourage proactive health conversations — not as a substitute for clinical diagnosis or medical advice.

A Digital Bridge Between Awareness and Action

“Early awareness is the first step toward better outcomes. This tool is designed to lower the barrier to proactive health engagement making it easier for individuals to understand their personal risk profile and take informed action,” said Dr. Ethan Shen, Chairman and Chief Executive Officer of YD Bio.

About EG BioMed

EG BioMed is a biotechnology and clinical services company focused on advancing early cancer detection and diagnostic solutions. YD Bio entered into a Memorandum of Understanding to merge with EG BioMed in January 2026 and is advancing the transaction, which is anticipated to close in 2026, subject to customary closing conditions, regulatory approvals, and the finalization of definitive agreements.

EG BioMed US is the U.S. clinical-laboratory subsidiary of EG BioMed and operates a CLIA-certified, CAP-accredited clinical laboratory in Bothell, Washington, focused on DNA methylation–based early cancer detection and AI-driven biomarker analytics. EG BioMed and EG BioMed US are affiliates of YD Bio.

About YD Bio Limited

YD Bio is a U.S.-anchored public biotechnology company building an integrated healthcare platform spanning regulated molecular diagnostics, clinical services, precision medicine, and life science commercialization. The Company operates DNA methylation–based oncology testing programs in the United States under a laboratory-developed test strategy and supports pharmaceutical and biotechnology partners through compliant life science distribution and clinical trial supply chain services. In addition, the Company maintains regulated ocular health commercialization operations and a consumer health distribution platform in Asia.

AI Cancer Risk Assessment
https://ai-cancer-risk.eg-bio.com/

Leave a Comment